ACIU

AC Immune SA

2.89

USD

ACIU Earnings Reports

Positive Surprise Ratio

ACIU beat 22 of 37 last estimates.

59%

Next Report

Date of Next Report

Apr 23, 2026

Estimate for Q1 26 (Revenue/ EPS)

$413.20K

-$0.17

Implied change from Q4 25 (Revenue/ EPS)

+22.25%

+30.77%

Implied change from Q1 25 (Revenue/ EPS)

-58.26%

-10.53%

AC Immune SA earnings per share and revenue

On Mar 13, 2026, ACIU reported earnings of -0.13 USD per share (EPS) for Q4 25, beating the estimate of -0.17 USD, resulting in a 24.29% surprise. Revenue reached 338.00 thousand, compared to an expected 1.17 million, with a -71.06% difference. The market reacted with a +0.50% price change (close before vs. close after earnings).

Looking ahead to Q1 26, -- analysts forecast an EPS of -0.17 USD, with revenue projected to reach 413.20 thousand USD, implying an increase of 30.77% EPS, and increase of 22.25% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were AC Immune SA's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, AC Immune SA reported EPS of -$0.13, beating estimates by 24.29%, and revenue of $338.00K, -71.06% below expectations.

How did the market react to AC Immune SA's Q4 2025 earnings?

The stock price moved up 0.5%, changed from $3.00 before the earnings release to $3.02 the day after.

When is AC Immune SA expected to report next?

The next earning report is scheduled for Apr 23, 2026.

What are the forecasts for AC Immune SA's next earnings report?

Based on -- analysts, AC Immune SA is expected to report EPS of -$0.17 and revenue of $413.20K for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.